Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3

Authors: Jun Xue, Yan-Feng Niu, Jing Huang, Gang Peng, Li-xia Wang, Yu-Hui Yang, Yun-Qiao Li

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

MicroRNAs (miRNAs) function as essential post-transcriptional modulators of gene expression involved in a wide range of physiologic and pathologic states, including cancer. Numerous miRNAs have been deregulated in hepatocellular carcinoma (HCC). Here, we investigated the role of miR-141 in HCC. Decreased expression of miR-141 was observed in both HCC tissues and cell lines. Ectopic overexpression of miR-141 reduced proliferation, migration, and invasion of HCC cells. E2F transcription factor 3 (E2F3) was confirmed to be a target of miR-141 in HCC cells. Moreover, restoration of E2F3 significantly reversed the tumor suppressive effects of miR-141. Our results suggest a critical role of miR-141 in suppressing metastasis of HCC cells by targeting E2F3.
Literature
1.
Tsochatzis EA, Meyer T, Burroughs AK. Hepatocellular carcinoma. The New England journal of medicine 2012;366:92. author reply 92–93.
2.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.CrossRef
3.
Herranz H, Cohen SM. MicroRNAs and gene regulatory networks: managing the impact of noise in biological systems. Genes Dev. 2010;24:1339–44.CrossRef
4.
Jiang HL, Yu H, Ma X, Xu D, Lin GF, Ma DY, Jin JZ. MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014.
5.
Zhang J, Jin H, Liu H, Lv S, Wang B, Wang R, Liu H, Ding M, Yang Y, Li L, Zhang J, Fu S, Xie D, Wu M, Zhou W, Qian Q. MiRNA-99a directly regulates AGO2 through translational repression in hepatocellular carcinoma. Oncogenesis 2014;3:e97.
6.
Long XR, He Y, Huang C, Li J. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J Oncol. 2014;44:1915–22.CrossRef
7.
Huang XH, Wang Q, Chen JS, Fu XH, Chen XL, Chen LZ, et al. Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res : Off J Jpn Soc Hepatol. 2009;39:786–94.CrossRef
8.
Wong CM, Wong CC, Lee JM, Fan DN, Au SL, Ng IO. Sequential alterations of microRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology. 2012;55:1453–61.CrossRef
9.
Zhang Y, Zheng D, Xiong Y, Xue C, Chen G, Yan B, et al. miR-202 suppresses cell proliferation in human hepatocellular carcinoma by downregulating LRP6 post-transcriptionally. FEBS Lett. 2014;588:1913–20.CrossRef
10.
Wu GG, Li WH, He WG, Jiang N, Zhang GX, Chen W, et al. miR-184 post-transcriptionally regulates SOX7 expression and promotes cell proliferation in human hepatocellular carcinoma. PloS one. 2014;9:e88796.CrossRef
11.
Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. miR-141 suppresses the migration and invasion of HCC cells by targeting Tiam1. PLoS One. 2014;9:e88393.CrossRef
12.
Xu L, Li Q, Xu D, Wang Q, An Y, Du Q, et al. hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Int J Oncol. 2014;44:459–66.CrossRef
13.
Tsang FH, Au V, Lu WJ, Shek FH, Liu AM, Luk JM, Fan ST, Poon RT, Lee NP. Prognostic marker microRNA-125b inhibits tumorigenic properties of hepatocellular carcinoma cells via suppressing tumorigenic molecule eIF5A2. Digestive diseases and sciences 2014.
14.
Liu YX, Long XD, Xi ZF, Ma Y, Huang XY, Yao JG, et al. MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. BioMed Res Int. 2014;2014:482926.PubMedPubMedCentral
15.
Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H, Zhang X. miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression. Clinical cancer research : an official journal of the American Association for Cancer Research 2014.
16.
Chen B, Huang T, Jiang J, Lv L, Li H, Xia S. miR-141 suppresses proliferation and motility of gastric cancer cells by targeting HDGF. Mol Cell Biochem. 2014;388:211–8.CrossRef
17.
Rady B, Chen Y, Vaca P, Wang Q, Wang Y, Salmon P, et al. Overexpression of E2F3 promotes proliferation of functional human beta cells without induction of apoptosis. Cell Cycle. 2013;12:2691–702.CrossRef
18.
Zeng X, Yin F, Liu X, Xu J, Xu Y, Huang J, et al. Upregulation of E2F transcription factor 3 is associated with poor prognosis in hepatocellular carcinoma. Oncol Rep. 2014;31:1139–46.CrossRef
19.
Bilke S, Schwentner R, Yang F, Kauer M, Jug G, Walker RL, et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer. Genome Res. 2013;23:1797–809.CrossRef
20.
Miles WO, Tschop K, Herr A, Ji JY, Dyson NJ. Pumilio facilitates miRNA regulation of the E2F3 oncogene. Genes Dev. 2012;26:356–68.CrossRef
21.
Ren XS, Yin MH, Zhang X, Wang Z, Feng SP, Wang GX, et al. Tumor-suppressive microRNA-449a induces growth arrest and senescence by targeting E2F3 in human lung cancer cells. Cancer Lett. 2014;344:195–203.CrossRef
22.
Zhang QQ, Xu H, Huang MB, Ma LM, Huang QJ, Yao Q, et al. MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion. Neuro-Oncology. 2012;14:278–87.CrossRef
23.
Su J, Wang Q, Liu Y, Zhong M. miR-217 inhibits invasion of hepatocellular carcinoma cells through direct suppression of E2F3. Molecular and cellular biochemistry 2014.
Metadata
Title
miR-141 suppresses the growth and metastasis of HCC cells by targeting E2F3
Authors
Jun Xue
Yan-Feng Niu
Jing Huang
Gang Peng
Li-xia Wang
Yu-Hui Yang
Yun-Qiao Li
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2513-9

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue

Research Article

Circulating miRNAs 21 and 221 as biomarkers for early diagnosis of prostate cancer

Research Article

Diagnostic significance of diffusion-weighted MRI in patients with cervical cancer: a meta-analysis

Research Article

Nobiletin suppresses the proliferation and induces apoptosis involving MAPKs and caspase-8/-9/-3 signals in human acute myeloid leukemia cells

Research Article

Identification of a suitable qPCR reference gene in metastatic clear cell renal cell carcinoma

Research Article

MiR-451 increases radiosensitivity of nasopharyngeal carcinoma cells by targeting ras-related protein 14 (RAB14)

Review

EGFR inhibitors and autophagy in cancer treatment
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits